Haemonetics Corp
NYSE:HAE
Haemonetics Corp
NYSE:HAE
Price:
93.37 USD
-1.92%
Updated:
May 8, 2024
Haemonetics Corp
Operating Income
|
Haemonetics Corp
Operating Income Peer Comparison
Comparables:
COO
XRAY
ALGN
LNTH
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Haemonetics Corp
NYSE:HAE
|
Operating Income
$199.3m
|
CAGR 3-Years
24%
|
CAGR 5-Years
13%
|
CAGR 10-Years
4%
|
|
|
Cooper Companies Inc
NYSE:COO
|
Operating Income
$536.7m
|
CAGR 3-Years
17%
|
CAGR 5-Years
5%
|
CAGR 10-Years
5%
|
|
|
DENTSPLY SIRONA Inc
NASDAQ:XRAY
|
Operating Income
$281m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-4%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Operating Income
$663.9m
|
CAGR 3-Years
7%
|
CAGR 5-Years
6%
|
CAGR 10-Years
14%
|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Operating Income
$474.4m
|
CAGR 3-Years
541%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
See Also
What is Haemonetics Corp's Operating Income?
Operating Income
199.3m
USD
199.3m
USD
Based on the financial report for Dec 30, 2023, Haemonetics Corp's Operating Income amounts to 199.3m USD.
What is Haemonetics Corp's Operating Income growth rate?
Operating Income CAGR 10Y
4%
4%
Over the last year, the Operating Income growth was 37%. The average annual Operating Income growth rates for Haemonetics Corp have been 24% over the past three years , 13% over the past five years , and 4% over the past ten years .
You don't have any saved screeners yet
